Investment in early detection will drive further progress in increasing survival rates, according to Diane Simeone, MD. Simeone spoke about the significance of these results in the context of the ...

A glimmer of hope may be on the horizon for a ruthless cancer that former Sen. Ben Sasse (R-Neb.) once called a “definite death sentence.” An experimental treatment from Revolution Medicines helped ...

A study co-led by UCLA found patients who received daraxonrasib, an investigational, first-in-class oral drug designed to block one of the primary drivers of pancreatic cancer, lived a median of 13.2 ...

Please provide your email address to receive an email when new articles are posted on . Daraxonrasib nearly doubled survival vs. chemotherapy for pretreated patients with metastatic pancreatic cancer.

Dutch and US studies paint different pictures of systemic therapy use in metastatic pancreatic cancer, but differences in patient preferences and data sources complicate direct comparisons.

FDA approves Rasonque, a first-in-class targeted therapy for metastatic pancreatic cancer, offering a new treatment option for eligible patients. The U.S. Food and Drug Administration (FDA) has ...

The Food and Drug Administration approved Revolution Medicines' promising pancreatic cancer drug on Aug. 26 after a clinical trial showed life expectancy nearly doubled for patients with disease that ...